Overview
Section 901(c) of the Pharmacy Benefit Reform Act, as amended by Act 77 of 2024, requires that the Insurance Department (Department) “publish guidance to effectuate … an efficient process by which a pharmacy may refer designation of a prescription drug under a health benefit plan.” The guidance will include a list of prescription drugs classified as specialty drugs. That list will include “the list of prescription drugs classified as a specialty drug under the Medical Assistance (MA) fee-for-service program,” but that (MA) list is “not to be considered exclusive.” The list in the guidance is published to facilitate the Department’s review of rates and forms for individual, small group, student health, and large group health benefit plans. The listing of prescription drugs not on the MA list is preliminary, tentative, and nonbinding for purposes of that review process. View Section 901(c) Guidance Specialty Drug List.
Submitting a Section 901(c) Referral
A pharmacy may refer to the Department pharmacy benefit manager’s (PBM’s) or health insurer’s designation of a particular drug as a specialty drug if, but only if, the designation was made by a (PBM) or a health insurer relating to prescription drug coverage under a health benefit plan, i.e., a fully-insured plan.
The Pharmacy should submit the referral to the Department’s Bureau of Consumer Services through the Pennsylvania Consumer Services Online Portal (CSO). They will evaluate whether the request is eligible for review.
When submitting a referral request, select “Other (PBM)” and “Pharmacy Benefit Manger” from the options available to ensure your request is assigned to the Section 901(c) Referral Review team.
For help using the CSO Portal view the CSO Portal Frequently Asked Questions.
Supporting Information
The referral should include as much of the following information as possible:
- Name and contact information of the PBM.
- Identification of the drug referred, including the RXCUI, if available.
- Information that will help the Department determine that the PBM’s specialty drug classification is related to a “health benefit plan” as defined under Act 77 of 2024. For example:
- A copy of the health insurance policy at issue, including the prescription drug coverage provisions.
- A copy of the covered person’s insurance card.
- Insurance or health plan name and contact information, including website, phone number, or email address.
- The name of the covered individual.
- Any other documents that confirm that the covered individual is provided pharmacy benefits by the health benefit plans, either directly or pursuant to a contract administered by a PBM.
- Information that will help the Department determine whether the drug meets the criteria for designating a drug as a specialty drug, including whether the drug:
- Requires specialized handling or administration.
- Requires specialized clinical care (including frequent dosing adjustments, clinical monitoring or expanded patient service, intensive patient counseling and ongoing clinical support).
- Is prescribed to address a rare, complex, chronic or life-threatening medical condition.
- Has a limited or exclusive distribution and is not typically stocked or dispensed by a retail pharmacy.
Section 901(c) Review Process
-
1
Step 1
Pharmacy files a referral with PID’s Bureau of Consumer Services
-
2
Step 2
PID determines if the referral is eligible.
- If the Department establishes that the request is ineligible for review or the Department is unable to confirm jurisdiction over the referral, the Department will notify both the pharmacy and the PBM identified by the pharmacy by letter and electronic mail.
- If the Department’s evaluation concludes that the Pharmacy’s request is eligible for review, the Department will forward the referral to the Department’s Administrative Hearings Office (AHO) for the opportunity for an administrative hearing.
-
3
Step 3
PID forwards the referral to the AHO.
- The request for review and any supporting documentation will be sent to the Department’s Administrative Hearings Office (AHO), copying both the pharmacy and the PBM on the transmittal letter.
-
4
Step 4
AHO conducts a hearing between the pharmacy and the PBM.
- At the hearing, both parties will have the opportunity to present witness testimony, offer documentary exhibits, and cross-examine the other party’s witnesses.
- At the conclusion of the hearing, the parties are afforded the opportunity to file written arguments in support of their position.
-
5
Step 5
The Insurance Commissioner issues a determination identifying whether the drug subject to the hearing is consistent with the statutory definition of “specialty drug.”
- Following the receipt of all evidence, the Insurance Commissioner will issue a determination through the AHO identifying whether the drug subject to the hearing is consistent with the statutory definition of “specialty drug” in section 103 of Act 77 of 2024.
-
6
Step 6
After the determination, either party has the right to request reconsideration and/or file an appeal with the Commonwealth Court.
- The request for reconsideration must be filed within fifteen (15) days of the determination.
- The appeal with the Commonwealth Court must be filed within thirty (30) days of the determination.
- Filing a request for reconsideration does not add time to the deadline for filing an appeal with the Commonwealth Court.
- The Department’s 901(c) adjudications will be made available online.
- Additionally, the Department will update the list of specialty drugs in accordance with any determinations made.
Questions?
For help or questions with the Specialty Drug Designation Referral Process, contact the Consumer Services Bureau by phone at 1-877-881-6388 or e-mail at ra-in-consumer@pa.gov.